ArticleAmerican journal of cancer research2020
CD4
Article in American journal of cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 24 citations in OpenAlex.
- Immune Exhaustion in Chronic Infection and Cancer: Signaling Pathways and Therapeutic Interventions.MedComm · 2026Review
- Nervous and immune system crosstalk shapes cancer progression and treatment response.Discover oncology · 2026Review
- CD4Cancer biology & medicine · 2026Review
- Adaptive-like CAR-iPSC-CD4⁺ T cells outperform CD8⁺ counterparts in sustained ALL control.Inflammation and regeneration · 2026Article
- Single-cell RNA sequencing unravels T cell exhaustion underlying the chronicity of chromoblastomycosis.Frontiers in immunology · 2026Article
- Immunotherapeutic potential of PD-1 blockade in chronic Leishmania mexicana infection through the enhancement of progenitor-like CXCR5Frontiers in immunology · 2026Article
- Dysfunctional CD4 T cells in an oncovirus-specific TCR-transgenic in vivo model.Nature communications · 2025Article
- Causal relationship between immune cells and bladder cancer: A bidirectional Mendelian randomization study.Medicine · 2025Article
- Cell-intrinsic CD4 T cell tolerance: a new frontier in therapy?Trends in immunology · 2025Review
- Development of therapeutic cancer vaccines based on cancer immunity cycle.Frontiers of medicine · 2025Review
- The tumor microenvironment of non-small cell lung cancer impairs immune cell function in people with HIV.The Journal of clinical investigation · 2025Article
- Methionine-driven YTHDF1 expression facilitates bladder cancer progression by attenuating RIG-I-modulated immune responses and enhancing the eIF5B-PD-L1 axis.Cell death and differentiation · 2025Article
- OX40/OX40L: a new target for tumor immunotherapy and its clinical research progress.Frontiers in oncology · 2025Review
- Nanoengineered-based delivery systems to modulate CD4Frontiers in pharmacology · 2025Review
- Multiomic profiling of chronically activated CD4+ T cells identifies drivers of exhaustion and metabolic reprogramming.PLoS biology · 2024Article
- Article
- CD39 expression defines exhausted CD4Clinical & translational immunology · 2024Article
- Effects of immune exhaustion and senescence of innate immunity in autoimmune disorders.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024Review
- The role of CD4MedComm · 2023Review
- Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8Journal for immunotherapy of cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Cytotoxic CD8
Indexed as
Identifiers
33414997PMC7783768W3119036133What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.